Navigation Links
Vermillion Reports Results for the Second Quarter 2011
Date:8/4/2011

ion in the same period last year. Operating expenses increased to $10.7 million for the six months ended June 30, 2011, compared to $7.2 million during the same period of 2010. These increases were primarily due to the increased payroll expenditures relating to hiring, investments in sales and marketing to accelerate the adoption of and reimbursement for OVA1, as well as an increase in clinical trial and collaboration costs for the ongoing development of the Company's ovarian cancer program and PAD blood test, VASCLIR™. The Company had 29 employees at June 30, 2011 compared to 17 employees at June 30, 2010. Operating expenses included $1.3 million and $2.5 million in non-cash stock-based compensation in the three and six months ended June 30, 2011, respectively. Non-cash stock-based compensation included in operating expenses in the three and six months ended June 30, 2010 was $1.2 million and $2.1 million, respectively.

Net loss for the second quarter was $5.7 million, or $0.39 per share, compared to $698,000, or $0.07 per share, for the same period in 2010. Other income and expense for the second quarter of 2010 included approximately $3.5 million of non-cash gains resulting from the fair value revaluation of common stock warrants. Weighted average shares outstanding were 14.7 million for the second quarter of 2011, compared to 10.3 million weighted average shares outstanding for the same period in 2010.

For the six months ended June 30, 2011, net loss was $10.0 million, or $0.73 per share, compared to $12.3 million, or $1.20 per share, for the same period in 2010. Other income and expense for the six months ended June 30, 2010 included approximately $8.5 million in reorganization items and $3.4 million of non-cash gains resulting from the fair value revaluation of common stock warrants. Weighted average shares outstanding were 13.6 million and 10.2 million for the six months ended June 30, 2011 and 2010, respectively.

Quarterly confe
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
2. Vermillion Announces Receipt of NASDAQ Panel Decision
3. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
4. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
5. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
6. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
7. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
8. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
9. Vermillion Announces Issuance of European Patent
10. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
11. Stephens Initiates Coverage on Vermillion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... Francis, WI (PRWEB) November 23, 2014 ... manufacturer and supplier of fine chemical ingredients to ... announced the launch of its new website, Apiscent.com. ... description of Apiscent Labs, clean design, easy navigation, ... that make Apiscent Labs stand out. ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... Richmond, VA (PRWEB) November 21, 2014 ... businessman who understood the need to surround himself with ... visionary, CEO and entrepreneur, his friends often marveled at ... how he lived his life and -- even with ... cure for the Alzheimer’s disease that would ultimately take ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Prominent ... investors will gather on December 3rd at Genetic ... Conferences series. GeneticRx will take place at the ... School and will discuss the present and future ... exon skipping, and gene editing—as well as the ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2
... and David Batey Ph.D. , ... , Abstract ... PCR (qPCR) protocol was used on the MJ Research DNA Engine ... probes, one labeled with VIC and the other labeled with FAM, were used ...
... Scholar, Department of Veterinary,Pathology, University of Glasgow, Bearsden Rd, Glasgow. G61 1QH. , ... , A method that can be ... of tissues for analysis in the Polymerase Chain Reaction is described. , ... low risk of inadvertent contamination , of samples ...
... Paul Zoller, Research and Development Department, Genetic Systems , ... 94547 , ... It has become clear that electroporation of E. coli results in ... , by a factor of 10 to 100, and ...
Cached Biology Technology:Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 2Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 3Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 4Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 5Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 6Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 7Preparation of PCR Quality Template DNA from a Wide Range of Tissues Using InstaGene Matrix 2Preparation of PCR Quality Template DNA from a Wide Range of Tissues Using InstaGene Matrix 3High Electrotransformation Efficiencies Obtained With DNA From Ligation Mixtures 2High Electrotransformation Efficiencies Obtained With DNA From Ligation Mixtures 3High Electrotransformation Efficiencies Obtained With DNA From Ligation Mixtures 4High Electrotransformation Efficiencies Obtained With DNA From Ligation Mixtures 5
(Date:11/5/2014)... Kelly Redmond has dedicated his career to understanding ... a general audience. , As deputy director and ... at Nevada,s Desert Research Institute, Redmond has more ... application and dissemination of climate data to the ... Meeting in San Francisco on December 15-19, 2014 ...
(Date:11/4/2014)... (November 4, 2014) — Think about the way our ... do neighboring cells know that they are supposed to ... do these tissues find the correct place and alignment? ... these crucial questions. , In a new study, UM ... communicate with their surrounding neighbors, at the head-trunk region. ...
(Date:11/3/2014)... 2014 Research and Markets has announced ... Technologies, Markets and Companies" to their offering. ... methods, which have already started to play an important role ... replacing the old fashioned bone marrow transplants. Role of cells ... to become a part of medical practice. Stem ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2The inside story: How the brain and skull stay together 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... Chris Field, professor of interdisciplinary environmental studies at Stanford ... (IPCC) Fifth AssessmentWorking Group II. WHAT: ... change that isfaster than at any time in the last ... on the topic. WHEN: Friday, Feb. ...
... Council (MRC) has announced 580,000 of funding to facilitate ... capacity in Africa focused on the health effects of ... identified as a major preventable cause of disease and ... The BREATHE Africa partnership (Biomass Reduction and Environmental ...
... society devoted to furthering research aimed at the understanding proteins, ... awards will be conferred at the 28th Annual Symposium of ... Plenary talks from each recipient are scheduled throughout the 3.5 ... by Rigaku Corporation, is given to an outstanding protein scientist ...
Cached Biology News:MRC funds BREATHE Africa partnership 2The Protein Society announces its 2014 award recipients 2The Protein Society announces its 2014 award recipients 3
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Monoclonal antibodies conjugated with rhodamine...
... p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl White ... Protein synthesis inhibitor. Inhibits translation by ... chains. Induces DNA fragmentation in thymocytes ... Purity: ≥98% by TLC. ...
Mouse monoclonal antibody to PPP2R2C - protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform...
Biology Products: